While the number of patients awaiting human tissues (allografts) continues to mount, the paucity of suitable donors limits the number of transplants that can be performed. Tissue from non human (xenogeneic) sources cannot be used since it is violently rejected. Nor are recipients of allografts returned to a completely normal life. Lifelong immunosuppression is required to prevent graft rejection leaving patients susceptible to infections and cancer. Thus there is a great need for new immunosuppressive agents which prevent allograft and xenograft rejection without significant side-effects. Testis has long been known as an """"""""immune privileged"""""""" site into which allografts and xenografts can be successfully transplanted. We have discovered that immune privilege is mediated by an immunoregulatory protein called CD95 ligand which is produced by testicular Sertoli cells. The experiments described below will further characterize the immunosuppressive attributes of CD95 ligand in transplant settings in mice. In addition, these studies will also begin to address our long term goal of creating universal """"""""CD95 ligand-protected"""""""" donor tissues to alleviate the current shortage of human tissues. Specifically, we will ask: l. Can CD95 ligand protect a tissue from a preexisting anti-graft immune response? 2. Can CD95 ligand-expressing tissue protect non-CD95L-expressing tissue transplanted in the same site from graft rejection? 3. Can CD95 ligand-expressing tissue induce tolerance to graft antigens such that subsequent non-CD95L-expressing tissue transplants are protected from graft rejection? 4. Can the gene encoding CD95 ligand be used to create immune privileged tissue suitable for transplant?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040607-05
Application #
6124391
Study Section
Immunobiology Study Section (IMB)
Program Officer
Kehn, Patricia J
Project Start
1996-12-01
Project End
2001-11-30
Budget Start
1999-12-01
Budget End
2001-11-30
Support Year
5
Fiscal Year
2000
Total Cost
$209,573
Indirect Cost
Name
Eleanor Roosevelt Institute for Cancer Research
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80206
Meech, S J; Edelson, R; Walsh, P et al. (2001) Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann N Y Acad Sci 941:46-58
Srikanth, S; Franklin, C C; Duke, R C et al. (1999) Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 199:169-78
Lin, B; Williams-Skipp, C; Tao, Y et al. (1999) NF-kappaB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type. Cell Death Differ 6:570-82
Hedlund, T E; Duke, R C; Miller, G J (1999) Three-dimensional spheroid cultures of human prostate cancer cell lines. Prostate 41:154-65
Duke, R C; Newell, E; Schleicher, M et al. (1999) Transplantation of cells and tissues expressing Fas ligand. Transplant Proc 31:1479-81
Desbarats, J; Duke, R C; Newell, M K (1998) Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med 4:1377-82
Hedlund, T E; Duke, R C; Schleicher, M S et al. (1998) Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 36:92-101